e-learning
resources
Munich 2014
Sunday, 07.09.2014
Rationale behind respiratory drug development
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry
H. Worth, R. Buhl, C. P. Criée, P. Kardos, C. Vogelmeier (Fuerth, Mainz, Bovenden, Frankfurt am Main, Marburg, Germany)
Source:
International Congress 2014 – Rationale behind respiratory drug development
Session:
Rationale behind respiratory drug development
Session type:
Thematic Poster Session
Number:
929
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Worth, R. Buhl, C. P. Criée, P. Kardos, C. Vogelmeier (Fuerth, Mainz, Bovenden, Frankfurt am Main, Marburg, Germany). Real life distribution of the COPD patients in GOLD groups A to D in German population: DACCORD registry. Eur Respir J 2014; 44: Suppl. 58, 929
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
What are common COPD symptoms in a real-life setting? The German DACCORD registry
Source: International Congress 2014 – COPD markers
Year: 2014
Distribution and outcomes of the new Spanish phenotype-based guideline for COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Pharmacological treatment of COPD in the on-sint cohort
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Assessment of patients with COPD according to previous and new GOLD: Which stage in which group?
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
Results of a pulmonary rehabilitation program (PRP) in COPD patients: Differences in outcomes according to currently 2011 GOLD groups
Source: International Congress 2014 – Best posters in pulmonary rehabilitation 2
Year: 2014
Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Disease progression and changes in risk groups' classification over a period of one year in the GPs based Swiss chronic obstructive pulmonary disease (COPD) cohort
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Distribution and significance of GOLD 2011 disease severity classification in patients with COPD in China: A national cross-sectional survey
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Drug treatment in a German real-life COPD cohort (DACCORD)
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015
Cluster analyses in a sample of COPD patients
Source: International Congress 2014 – Best posters in pulmonary rehabilitation 1
Year: 2014
Clinical trials for elderly patients with multiple diseases (CHROMED): A pilot study
Source: International Congress 2014 – The assessment of comorbidities
Year: 2014
Characteristics and outcomes of GOLD C and D COPD patients
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014
Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
The 2013 updated GOLD strategy: A comparison of the various scenarios
Source: International Congress 2014 – Best abstracts in chronic care
Year: 2014
Impact of chronic obstructive pulmonary disease (COPD) and patients' absence from work in Greece - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Validation of the COPD control concept: A UK pilot
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
Late Breaking Abstract - Adherence to GOLD recommendations in Italian COPD patients stratified by GOLD groups A–D: The MISTRAL study
Source: International Congress 2017 – Primary care pulmonary rehabilitation, multimorbidity and organisation of care
Year: 2017
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept